Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Conference Paper

Full Text

Link to Item

Duke Authors

Halabi, Susan

Cited Authors

Choueiri, TK; Hessel, C; Halabi, S; Sanford, B; Hahn, O; Michaelson, MD; Walsh, M; Olencki, T; Picus, J; Small, EJ; Dakhil, S; Scheffold, C; George, DJ; Morris, MJ

Published Date

September 1, 2017

Published In

Annals of Oncology

Volume / Issue

28 /

Published By

OXFORD UNIV PRESS

Pages

1

Electronic International Standard Serial Number (EISSN)

1569-8041

International Standard Serial Number (ISSN)

0923-7534

Conference Name

42nd European-Society-for-Medical-Oncology Congress (ESMO)

Conference Location

Madrid, SPAIN

Conference Start Date

September 8, 2017

Conference End Date

September 12, 2017